Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Johnson & Johnson
  6. News
  7. Summary
    JNJ   US4781601046

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-08-12 pm EDT
165.30 USD   -1.10%
08/12Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scrutiny from Consumer Litigation, Science
PR
08/12J&J to end sales of baby powder with talc globally next year
AQ
08/12There are two ways to see inflation data
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab in Multiple Myeloma

06/29/2022 | 10:00am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about JOHNSON & JOHNSON
08/12Johnson & Johnson Ends Global Sales of Cancer-Causing Baby Powder Amid Increased Scruti..
PR
08/12J&J to end sales of baby powder with talc globally next year
AQ
08/12There are two ways to see inflation data
MS
08/12Johnson & Johnson To Discontinue Selling Talc-Based Baby Powder In 2023
MT
08/12MARKETSCREENER'S WORLD PRESS REVIEW : August 12, 2022
MS
08/12Johnson & Johnson's Janssen Secures License to WuXi's TESSA Technology
MT
08/12Johnson & Johnson to end global sales of talc-based baby powder in 2023
AQ
08/12Reuters-schedule/…
RE
08/11J&J to end sales of talc-based powder worldwide in 2023
AQ
08/11JOHNSON & JOHNSON : Consumer Health to Transition Global Baby Powder Portfolio to Cornstar..
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 604 M - -
Net income 2022 21 415 M - -
Net cash 2022 10 065 M - -
P/E ratio 2022 20,2x
Yield 2022 2,65%
Capitalization 435 B 435 B -
EV / Sales 2022 4,44x
EV / Sales 2023 4,17x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 165,30 $
Average target price 185,55 $
Spread / Average Target 12,3%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-3.37%434 603
ELI LILLY AND COMPANY11.53%292 730
PFIZER, INC.-15.14%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.32%252 131
NOVO NORDISK A/S4.76%240 550